Key Takeaways:
- Nearly two-thirds (62%) of manufacturing leaders believe tariffs and trade barriers make it more difficult to ensure product quality, creating supply chain vulnerabilities for regulated industries.
- A significant portion of manufacturers (40%) do not have a clear metric for the Cost of Quality (COQ), posing hidden financial and compliance risks.
- Despite advancements in automation, 73% of companies still rely on manual inspection as their primary quality control method, creating critical bottlenecks and potential for error.
In an environment of increasing regulatory scrutiny and complex global supply chains, medical device manufacturers face mounting pressure to maintain product quality without compromising cost-competitiveness. A new report from manufacturing intelligence firm Lumafield highlights how macroeconomic forces, particularly shifting trade policies, are adding a significant layer of risk to quality assurance operations.
The study, which surveyed over 200 quality leaders across the U.S. and Canada, found that external pressures are directly impacting internal quality metrics. The findings are particularly relevant for sectors like medical devices, where component integrity and product reliability are paramount.
Global Trade Policies Complicate Quality Control
The primary finding of the report reveals a widespread concern over international trade dynamics. Sixty-two percent of respondents believe that tariffs and other trade barriers have made it harder to ensure product quality. For medical device manufacturers who often rely on a global network of specialized component suppliers, these barriers can disrupt established supply chains, force costly re-sourcing, and introduce risks from new, unvetted suppliers.
Supplier-related issues were cited as the top quality concern across all industries surveyed. Forty-one percent of leaders indicated that a 25% reduction in costs from these issues would have the greatest operational impact, underscoring the financial and logistical strain caused by supply chain instability.
The Hidden Costs of Unmeasured Quality
While quality control is a universal business expense, the study found that many companies lack a precise understanding of its financial impact. Forty percent of respondents reported that their organization does not have a clear, established metric for the Cost of Quality (COQ). This lack of visibility can obscure significant inefficiencies and potential failure points, leading to unexpected costs from scrap, rework, and product recalls.
“Rising trade barriers and component shortages are creating a minefield for manufacturers,” says Eduardo Torrealba, Co-Founder and CEO of Lumafield. “Quality has a cost, and if you aren't accurately measuring it, you’re essentially gambling with your margins.”
Technology Gap in Inspection Persists
Despite the availability of advanced inspection technologies, the report highlights a persistent reliance on traditional methods. A majority of companies (73%) still use manual inspection as their primary quality control process. This dependence on manual processes can be a major bottleneck, slowing down production and introducing the risk of human error—a critical liability in the manufacturing of sterile and medical-grade products.
Torrealba noted the opportunity for technology to address these gaps. “The research shows an enormous and real technology opportunity as AI and automated inspection are delivering measurable gains in efficiency,” he says. “But those benefiting the most from this are the ones that have built the data infrastructure to actually make the technology useful.”
For decision-makers in the medical device industry, the report suggests that navigating today's economic landscape requires a dual focus on shoring up supply chain resilience and investing in the data infrastructure needed to adopt more advanced, reliable quality assurance technologies.
Research Methodology
The survey was completed in partnership with NewtonX, an independent research firm, and reflects responses from more than 200 professionals with decision-making power in quality and inspection across industries in the U.S. and Canada. The study captures a diverse cross-section of the manufacturing landscape, with heavy representation from the aerospace and defense, automotive, consumer electronics, consumer packaged goods (CPG), and Medical Devices sectors.
Lumafield also conducted follow-up interviews with eight survey respondents to gain a deeper understanding of the trends the survey revealed.
